[KLK] QoQ TTM Result on 31-Dec-2017 [#1]

Announcement Date
12-Feb-2018
Admission Sponsor
-
Sponsor
-
Financial Year
30-Sep-2018
Quarter
31-Dec-2017 [#1]
Profit Trend
QoQ- -3.98%
YoY- -16.63%
View:
Show?
TTM Result
30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 CAGR
Revenue 18,400,500 19,373,306 19,914,758 20,700,428 21,004,036 20,383,215 19,432,520 -3.56%
PBT 1,117,380 1,327,992 1,312,679 1,419,298 1,450,205 1,313,371 1,426,282 -15.00%
Tax -313,276 -361,619 -374,059 -385,956 -383,329 -110,535 -81,572 145.03%
NP 804,104 966,373 938,620 1,033,342 1,066,876 1,202,836 1,344,710 -29.00%
-
NP to SH 753,328 893,952 864,785 965,081 1,005,130 1,138,063 1,278,694 -29.70%
-
Tax Rate 28.04% 27.23% 28.50% 27.19% 26.43% 8.42% 5.72% -
Total Cost 17,596,396 18,406,933 18,976,138 19,667,086 19,937,160 19,180,379 18,087,810 -1.81%
-
Net Worth 11,427,081 11,235,388 11,075,642 11,576,176 11,576,176 11,341,884 11,448,381 -0.12%
Dividend
30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 CAGR
Div 159,744 532,482 532,482 532,482 532,482 532,482 532,482 -55.15%
Div Payout % 21.21% 59.57% 61.57% 55.17% 52.98% 46.79% 41.64% -
Equity
30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 CAGR
Net Worth 11,427,081 11,235,388 11,075,642 11,576,176 11,576,176 11,341,884 11,448,381 -0.12%
NOSH 1,064,965 1,064,965 1,064,965 1,064,965 1,064,965 1,064,965 1,064,965 0.00%
Ratio Analysis
30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 CAGR
NP Margin 4.37% 4.99% 4.71% 4.99% 5.08% 5.90% 6.92% -
ROE 6.59% 7.96% 7.81% 8.34% 8.68% 10.03% 11.17% -
Per Share
30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 CAGR
RPS 1,727.80 1,819.15 1,869.99 1,943.76 1,972.27 1,913.98 1,824.71 -3.56%
EPS 70.74 83.94 81.20 90.62 94.38 106.86 120.07 -29.69%
DPS 15.00 50.00 50.00 50.00 50.00 50.00 50.00 -55.15%
NAPS 10.73 10.55 10.40 10.87 10.87 10.65 10.75 -0.12%
Adjusted Per Share Value based on latest NOSH - 1,064,965
30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 CAGR
RPS 1,674.31 1,762.83 1,812.10 1,883.59 1,911.22 1,854.73 1,768.22 -3.56%
EPS 68.55 81.34 78.69 87.82 91.46 103.56 116.35 -29.69%
DPS 14.54 48.45 48.45 48.45 48.45 48.45 48.45 -55.14%
NAPS 10.3978 10.2234 10.078 10.5335 10.5335 10.3203 10.4172 -0.12%
Price Multiplier on Financial Quarter End Date
30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 CAGR
Date 28/09/18 29/06/18 30/03/18 29/12/17 29/09/17 30/06/17 31/03/17 -
Price 24.96 24.16 25.58 25.00 24.56 24.88 24.68 -
P/RPS 1.44 1.33 1.37 1.29 1.25 1.30 1.35 4.39%
P/EPS 35.29 28.78 31.50 27.59 26.02 23.28 20.55 43.35%
EY 2.83 3.47 3.17 3.62 3.84 4.30 4.87 -30.34%
DY 0.60 2.07 1.95 2.00 2.04 2.01 2.03 -55.59%
P/NAPS 2.33 2.29 2.46 2.30 2.26 2.34 2.30 0.86%
Price Multiplier on Announcement Date
30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 CAGR
Date 14/11/18 14/08/18 16/05/18 12/02/18 22/11/17 15/08/17 22/05/17 -
Price 24.92 24.86 25.40 25.24 24.50 24.68 24.84 -
P/RPS 1.44 1.37 1.36 1.30 1.24 1.29 1.36 3.88%
P/EPS 35.23 29.62 31.28 27.85 25.96 23.09 20.69 42.54%
EY 2.84 3.38 3.20 3.59 3.85 4.33 4.83 -29.79%
DY 0.60 2.01 1.97 1.98 2.04 2.03 2.01 -55.30%
P/NAPS 2.32 2.36 2.44 2.32 2.25 2.32 2.31 0.28%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment